Veeva Systems (VEEV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this provider of cloud-based software services for the life sciences industry have returned -4.3% over the past month versus the Zacks S&P 500 composite's +1.3% change. The Zacks Internet - Software industry, to which Veeva belongs, has gained 5.6% over this period. Now the key question is: Where cou ...

More than 125 medtech customers use Veeva applications for seamless execution across product development PLEASANTON, Calif., Oct. 2, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 18 of the top 20 medtech companies leverage Veeva Development Cloud and Veeva Commercial Cloud applications to streamline processes across the total medtech product lifecycle. Veeva MedTech enables more than 125 customers with deep industry expertise and technology from ideation to commercialization. With an ...

A month has gone by since the last earnings report for Veeva Systems (VEEV) . Shares have lost about 3.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Veeva due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Veeva Systems Q2 Earnings & Revenues Beat, Operating Ma ...

Veeva Systems Inc. (VEEV) announced the expansion of Veeva Vault QMS yesterday. The expansion is expected to add new capabilities to manage MedTech field actions and product recalls. The latest availability of expanded features is expected to significantly boost Veeva Systems' Vault Quality suite and solidify its foothold in the niche space. Likely Trend of VEEV Stock Following the News Following the announcement on Sept. 24, 2024, shares of the company moved nearly 1.5% south to $207.91 at yesterday's clos ...

Veeva Systems Inc. (VEEV) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2025 performance and strategic deals, is expected to contribute further. Stiff competition and rising operational costs persist. This Zacks Rank #3 (Hold) company's shares have gained 8% in the year-to-date period compared with 20.9% growth of the industry. The S&P 500 Composite has risen 20.2% during the said time frame. The renowned provid ...

Core Insights - Veeva Systems has expanded its Veeva Vault QMS to enhance management of medtech field actions and product recalls, improving oversight, timeliness, and accuracy throughout the process [1][2][3] Group 1: New Capabilities - The new features in Veeva Vault QMS will facilitate the entire field action process, including issue identification, evaluation, planning, execution, and monitoring through to closure [1] - The integration of field actions and recall management with adjacent quality processes such as complaint handling and quality risk management reduces manual transcription needs, thereby enhancing efficiency [2] Group 2: Industry Collaboration - Veeva has collaborated closely with industry partners like Teleflex to develop these capabilities, aiming to streamline processes and improve customer service [2] - The company emphasizes the importance of understanding industry needs to deliver solutions that enhance agility in critical processes related to product quality and patient safety [3] Group 3: Company Overview - Veeva Systems is recognized as a global leader in cloud software for the life sciences sector, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [4] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, and shareholders [4]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...

Veeva Systems (VEEV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VEEV broke through the 20-day moving average, which suggests a short-term bullish trend. The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages. Sim ...

Company Performance - Veeva Systems' shares have increased by 20.5% over the past three months, outperforming both the industry and the S&P 500 Index, driven by strong quarterly results, product expansion, and new partnerships [1] - The company reported a 15% increase in revenue year-over-year for the second quarter, with a 19% rise in recurring subscriptions, exceeding market expectations [2] - Veeva achieved a 32% improvement in operating profit and generated nearly $850 million in free cash flow during the first two quarters of fiscal 2025 [4] Revenue and Earnings Guidance - Veeva raised its revenue guidance for fiscal 2025 to between $2,704 million and $2,710 million, slightly above previous estimates [5] - Subscription revenues for fiscal 2025 are now expected to be $2,257 million, an increase from the prior outlook of $2,245 million [6] - Adjusted EPS for fiscal 2025 is projected to be $6.22, up from the previous guidance of $6.16 [7] New Partnerships and Product Developments - Veeva introduced new capabilities to its Veeva Site Connect, enhancing sponsor-site collaboration for clinical trials, which is expected to reduce trial time and costs [8] - The company partnered with Vita Global Sciences to enhance clinical data management, aiming for faster trials and improved patient outcomes [9] - Hangzhou Tigermed Consulting also signed a deal with Veeva to modernize electronic data capture and streamline data management processes [10] Industry Prospects - The global clinical data management system market is projected to grow from $2.3 billion in 2022 to $5.42 billion by 2030, at a CAGR of 11.3%, driven by an increase in clinical trials and integration with healthcare technologies [11]

The cloud software leader charged higher after a strong quarterly earnings report. Shares of Veeva Systems (VEEV 3.10%) rose 12.8% in August, according to data provided by S&P Global Market Intelligence. The company reported excellent quarterly financial results, and the stock's attractive valuation translated to gains as investors revised their forecasts higher. Veeva had a stellar quarterly report Veeva reported quarterly earnings on Aug. 28, sending the stock higher. The company achieved 15% revenue grow ...